Tiantian Bio announced that TJ107 has completed the first patient drug treatment in Phase 2 clinical studies in China

On February 4, Tiantian Bio announced that its new long-acting recombinant human lebinocyte interlethional 7 (rhIL-7) TJ107 treatment of glioblastoma in China Phase 2 clinical trial has completed the first patient drug.
the clinical trial was a randomized, single-blind, placebo-controlled study designed to assess the efficacy and safety of TJ107 in patients with reduced lymphocytes after the completion of standard synchronous chemotherapy (CCRT) in the newly diagnosed glioblastoma patient population.
the study was designed to determine the count of lymphocytes and associated clinical responses after TJ107 was first given.
more and more studies have shown that lymphocyte reduction caused by radiotherapy and chemotherapy is associated with low immune function and is significantly associated with low survival rates in cancer patients.
existing standard treatment for glioblastoma induces a lasting reduction in lymphocytes in most patients, and there is currently a lack of targeted therapy.
clinical study conducted by Genexine Korea (KOSDAQ:095700) shows that in patients with advanced solid tumors, TJ107 can increase the count of anti-tumor lymphocytes, especially by restoring the initial and memory of the T-cell substation (non-regulatory T-cells).
studies have also shown that TJ107 is well-to-doted and has no dose-restricted toxicity or cytokine release syndrome.
About TJ107/GX-I7TJ107/GX-I7 (efineptakin alfa, efineptakin alfa) is the world's first and only long-acting recombinant human leukocyte interleukin 7 (rhIL-7), which promotes T lymphocyte proliferation by increasing the number of T lymphocytes and improving T-cell function.
long-acting biologics developed by the company for the ® geneexine patented technology platform hyFc.
has obtained an exclusive license for clinical development and commercialization of TJ107/GX-I7 in Greater China.
TJ107/GX-I7 may play a role in the reduction of lymphocytes associated with cancer treatment (lower levels of outer blood lymphocytes).
lymphocytes is a common phenomenon in cancer patients after chemotherapy or radiotherapy, and there is currently no approved targeted therapy.
also shown in various tumor animal models that TJ107/GX-I7 may have synergies with PD-1 antibodies by increasing T cell activation and proliferation.
note: There are deletions in the original text